Bernstein sees TI’s likely price hike benefiting Infineon, Renesas stock
On Thursday, JPMorgan increased its price target for Alnylam Pharmaceuticals shares, now aiming for a $330.00 valuation. The biopharmaceutical company, traded under (NASDAQ:ALNY), specializes in RNA interference (RNAi) therapeutics. Currently trading at $292.09 with a market capitalization of $38 billion, the stock has delivered an impressive 94% return over the past year. This adjustment by JPMorgan reflects a positive outlook on the company’s financial health and market performance. According to InvestingPro, the company shows several promising indicators, with 12 key insights available to subscribers.
The updated price target suggests that JPMorgan analysts, led by Jessica Fye, maintain an optimistic view on Alnylam Pharmaceuticals’ prospects. This optimism is supported by recent data showing 17.2% revenue growth and seven analysts revising their earnings estimates upward for the upcoming period. The firm’s previous price target was not mentioned in the context provided, but the new target indicates heightened expectations for the stock’s potential growth.
Alnylam Pharmaceuticals has been pioneering RNAi therapeutics, a novel approach to drug development that targets the genetic basis of diseases. This innovative method has garnered significant attention in the pharmaceutical industry for its potential to treat a wide range of conditions. For detailed analysis of Alnylam’s financial health and growth prospects, investors can access comprehensive Pro Research Reports through InvestingPro.
The company’s stock performance and financial results are closely watched by investors, as developments in its drug pipeline can significantly impact its valuation. JPMorgan’s revised price target is a response to such factors, although specific reasons for the increase were not detailed in the context given.
Investors typically consider changes in price targets from major financial institutions as indicators of a stock’s future performance. While JPMorgan’s new target for Alnylam Pharmaceuticals is a positive sign, it remains one of many factors that can influence investment decisions.
In other recent news, Alnylam Pharmaceuticals reported its Q1 2025 earnings, surpassing expectations with an earnings per share (EPS) of -0.01, significantly better than the forecasted -0.93. The company also exceeded revenue projections, reporting $594.19 million compared to the anticipated $588.75 million, marking a 28% increase year-over-year. This growth was largely driven by the TTR franchise, which saw a 36% increase. H.C. Wainwright reaffirmed its Buy rating for Alnylam, maintaining a price target of $500, citing the strong performance of AMVUTTRA (vutrisiran) as a key factor. Stifel also maintained a Buy rating with a $345 target, highlighting the potential of Alnylam’s new drug, Amvuttra, in treating cardiomyopathy.
Alnylam’s shareholders recently approved an executive compensation plan and ratified PricewaterhouseCoopers LLP as the company’s independent auditors for the fiscal year ending December 31, 2025. The company plans to present new data from its transthyretin amyloidosis programs at the Heart Failure 2025 Congress, showcasing results from the HELIOS-B Phase 3 study on vutrisiran. Additionally, Alnylam is preparing to initiate several clinical programs in 2025, including the TRITON-CM Phase 3 trial for nucresiran, a next-generation TTR silencer. These developments are part of Alnylam’s strategic plan to achieve sustainable non-GAAP operating profitability and expand its portfolio of investigational medicines.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.